Financings

Acadia Pharmaceuticals Inc. priced about 10.3 million shares of common stock at $29 each for gross proceeds of about $300 million.

Acceleron Pharma Inc. priced an underwritten public offering of 3.75 million shares of common stock at $40 per share for gross proceeds of $150 million.

Aeterna Zentaris Inc. filed a preliminary short-form base shelf prospectus in Canada and the U.S. to offer up to $150 million of various securities.

Akebia Therapeutics Inc. priced 7.25 million shares at $9 each for gross proceeds of $65.3 million.

Audentes Therapeutics Inc. filed with the SEC to raise up to $86 million in an IPO.

C4 Therapeutics raised $73 million from a series A financing.

Cancer Prevention Pharmaceuticals Inc. filed to raise up to $30.1 million in an IPO on the NYSE.

Cempra Inc. priced about 4.2 million shares of common stock at $24 per share for gross proceeds of about $100 million.

Corvus Pharmaceuticals Inc. filed an S-1 with the SEC seeking to raise up to $115 million in an IPO.

Editas Medicine Inc. filed an S-1 with the SEC seeking to raise up to $100 million, including overallotments, in an IPO.

Epizyme Inc. priced 13.3 million shares at $9 per share for gross proceeds of about $120 million.

Millendo Therapeutics Inc. closed a $62 million series B financing round.

Proteostasis Therapeutics Inc. has filed to raise up to $86.3 million in an IPO on Nasdaq.

Prothena Corp. plc priced 2.25 million shares at $53 each for gross proceeds of about $119.3 million.

Reata Pharmaceuticals Inc. filed with the SEC seeking to raise up to $80 million in an IPO.

Sage Therapeutics Inc. priced about 3.2 million shares at $47.50 per share for gross proceeds of about $150 million.

Scholar Rock Inc. completed a $36 million series B financing.

Spring Bank Pharmaceuticals Inc. filed its S-1 with the SEC to raise up to $57.5 million in an IPO.

Syndax Pharmaceuticals Inc. re-filed with the SEC for an IPO of up to $86 million.

Visterra Inc. has filed to raise up to $69 million from a proposed IPO.

Deals

Agenus Inc. completed the acquisition of Xoma Corp.'s antibody manufacturing pilot plant and capabilities.

Allergan plc said it acquired Anterios Inc., a clinical-stage firm developing a next-generation delivery system and botulinum toxin-based prescription products.

Applied Genetic Technologies Corp. and the BCM Families Foundation, an organization focused on eradicating blue cone monochromacy, inked a collaboration to develop an adeno-associated virus-based gene therapy for the disease.

Araim Pharmaceuticals Inc. formed a strategic partnership with Vault Bioventures to help advance its peptide library, which targets injuries and chronic diseases with unmet medical needs.

Fibrocell Science Inc. is collaborating Intrexon Corp. for the development of genetically modified fibroblasts to treat chronic inflammatory and degenerative diseases of the joint.

Global Genomics Group will work with Sanofi SA to identify new signaling pathways and targets involved in the etiology of coronary artery disease.

Kinemed Inc. will work with Pfizer Inc. to discover and develop biomarkers in various fields of unmet medical need.

Lattice Biologics Inc. completed its merger with Blackstone Ventures Inc.

Medicure Inc. said it started developing a cardiovascular generic drug in collaboration with Apicore US LLC.

Merck KGaA, Pfizer Inc. and Syndax Pharmaceuticals Inc. are collaborating to study avelumab combined with entinostat, Syndax's oral small molecule, which targets immune regulatory cells in those who have heavily pretreated, recurrent ovarian cancer.

Merus BV and Institut Gustave Roussy inked a collaborative agreement to develop bispecific antibodies for immuno-oncology therapeutics.

Oncodesign SA is collaborating with Bristol-Myers Squibb Co. to discover, develop and commercialize macrocyclic compounds.

Rani Therapeutics LLC is collaborating with Medimmune, the biologics arm of London-based Astrazeneca plc, to evaluate its oral drug delivery system.

Rodin Therapeutics Inc. has landed a multiyear neuronal epigenetics R&D deal with Biogen Inc. that includes an undisclosed up-front payment for an option to buy the small cognitive disorders specialist.

Sanofi SA has handed back rights to inhaled insulin Afrezza to Mannkind Corp.

Symphogen A/S signed an alliance with Baxalta Inc. focused on up to six immune checkpoint targets, under which it is getting $175 million up front plus up to $1.6 billion more in option fees and milestone payments.

. . . And More

Amag Pharmaceuticals Inc. said its board approved a share repurchase program under which the company may purchase up to $60 million of its common stock.

CTI Biopharma Corp. and Baxalta Inc. said the rolling submission of the new drug application for pacritinib to the FDA has been completed.

Pluristem Therapeutics Inc. said the FDA granted its PLX-PAD cells orphan drug designation to treat severe preeclampsia.

The FDA gave the green light to 45 new molecular entities and new therapeutic biological products in 2015, an almost 10 percent increase over the number that were approved in 2014.